I I
n the United States, drug users have been disproportionately affected by the AIDS epidemic. As a result, the substance abuse research community has devel oped substantial knowledge about how to prevent HIV infection and systems to facilitate the management of those already infected. Yet, the drug treatment prac titioner's current knowledge of hepatitis, particularly hepatitis C, is similar to what was known about AIDS a decade ago. There is a growing, but still incomplete, understanding of the transmission of hepatitis C, its acute presentation, and how it behaves as a chronic infection. Treatment is available for chronic hepatitis C.
While treatment effectiveness may be limited, the importance of detecting hep atitis C infection, particularly acute (new-onset) infection, has been bolstered by recent evidence that treatment during the acute stage may prevent the estab lishment of chronic infection (Jaeckel et al., 2001 ).
In drug treatment programs, addressing medical issues such as infectious dis eases may be secondary to the goal of reducing patients' drug abuse. Staff mem bers in drug treatment programs may wonder how much attention they should
give to these problems, particularly if they feel they have little to offer clients by way of prevention or treatment. Nevertheless, by decreasing drug use and HIV risk behaviors and by educating patients about HIV, drug abuse treatment has become one of the most powerful AIDS prevention techniques in our public health arsenal. With adequate funding and public health support, drug abuse treatment programs can play a central role in preventing and detecting hepatitis as well.
Drug abuse treatment providers have unequaled opportunity to reach drug abusers with health infor mation and interventions. This article presents a num ber of suggestions, based on research, about what a drug treatment program can do to address HIV and hepatitis infections. First we review the extent of these infections among drug users. Then we discuss tech niques for using research-developed assessment and diagnostic tools. Finally, we suggest primary and sec ondary preventive activities that a treatment program can implement to limit the spread and consequences of infection.
PREVALENCE OF HIV AND HEPATITIS AMONG DRUG USERS
The prevalence of HIV among drug users entering treatment varies across different settings, ranging from 0 to 35 percent. Some transmission of HIV contin ues among those in drug abuse treatment, especially younger injecting drug users (IDUs) (Murrill et al., 2001) . IDUs are at high risk of infection with HIV and hepatitis A, B, and C viruses through unsterile injection practices and unsafe sexual behaviors. Injection drug use is a factor in one-third of all AIDS cases in the United States, more than one-half of new HIV infections, and one-half of new hepatitis C infections. IDUs as a group have high prevalence of viral hepa titis: Approximately 40 to 70 percent develop hepa titis A infection at some time in their injection careers, while their prevalence rates for hepatitis B and C are 50 to 90 percent. Some noninjecting users of illicit drugs, such as crack smokers, are also at risk of con tracting viral hepatitis.
Hepatitis is an inflammation of the liver, most often caused by alcohol or a virus. In the past, health providers often assumed that nearly all drug users were infected with hepatitis A and B by the time they entered drug abuse treatment, but today significant numbers of drug users in the community are free of these viruses. Thus, many patients entering treatment could ben efit from vaccines to protect against hepatitis A and B. Although many or most IDUs become infected with hepatitis C during their first year of injecting, some patients entering treatment programs are still uninfected and susceptible.
TRANSMISSION OF HIV AND HEPATITIS
HIV is transmitted through sharing of unsterile syringes and through unprotected sexual activity. The virus may also be transmitted from mother to child during birth and the weeks before and after-the perinatal period. New data suggest that sexual transmission of HIV is also an important mode among IDUs: Male IDUs who have sex with men and female IDUs who trade sex for money are more likely to become HIVinfected than IDUs who do not engage in those behav iors (Kral et al., 2001) .
There is significant overlap between modes of transmission and hence between risk factors for HIV and hepatitis A, B, and C. Because HIV and hepati tis are transmitted by many of the same routes, riskreduction efforts aimed at HIV transmission have also reduced the spread of hepatitis. However, hepatitis can be transmitted in more ways than HIV. Hepatitis A and B may be transmitted to household members and other close contacts who are not sexual partners.
Hepatitis A is spread through unsanitary living conditions, inadequate personal hygiene, and direct or indirect anal-oral contact, including sexual behav iors. Transmission of the virus in feces predominates, but hepatitis A is also transmitted via contact with contaminated drug injection equipment. Use of con taminated water to prepare drugs and contamination of drugs hidden in the rectum may play a role. Hepatitis A causes acute, not chronic, inflammation of the liver.
Hepatitis B virus is found in the semen, blood, and saliva of infected persons and is usually spread by contaminated syringes and unprotected sexual con tact. From 1 to 10 percent of patients develop chronic liver inflammation, which may progress to cirrhosis and liver cancer.
Hepatitis C virus is transmitted through con taminated blood (for example, during syringe shar ing) and through needle-stick injuries and unprotected sexual contact. In addition, recent research shows hep atitis C transmission associated with the sharing of unsterile injection equipment other than syringes (cookers, filtration cotton, rinse water) (NIDA, 2000) . Hepatitis C appears to spread more rapidly among IDUs than does HIV, because of higher prevalence of hepatitis C among injection partners and a higher infectivity of hepatitis C once it gets into the blood stream (Garfein et al., 1996; Hagan and Des Jarlais, 2000) . From 10 to 60 percent of individuals infected with hepatitis C virus develop some form of chronic liver inflammation.
Drug abuse treatment and interventions such as syringe exchange and outreach, which have focused on reducing the use of contaminated syringes, have been associated with lower incidence of HIV infec tion but have had less consistent or no effects on new cases of hepatitis C. To affect the transmission of hep atitis C, risk-reduction interventions are needed that address not only syringe use, but also sexual behav iors and the use of injection paraphernalia in addition to syringes (such as filtration cottons, cookers, and rinse water).
STAFF ASSESSING PATIENTS' RISKS Tools Available
Drug abuse treatment programs can incorporate risk assessment and educational messages about HIV risks into their intake and counseling protocols. The assessment must be done with an instrument that can reliably measure both drug-related and sex-related risk behaviors. Several self-report measures have been designed to assess drug use, injection practices, and sexual behaviors associated with HIV risk. Among the most widely used instruments are three that have demonstrated high reliability and validity: the Risk Behavior Assessment Questionnaire (NIDA, 1991), the Risk Assessment Battery (Treatment Research Institute, www.tresearch.org/Assessment%20Inst /Assess_inst.html), and the Texas Christian University (TCU) AIDS Risk Assessment (Camacho et al., 1997; www.ibr.tcu.edu) .
The Risk Assessment Battery Questionnaire and TCU AIDS Risk Assessment may be particularly use ful in clinical settings because they can be adminis tered in 15 minutes or less and require minimal staff training. A computerized version of the Risk Assessment Battery is as accurate as the paper-and-pencil ver sion (Navaline et al., 1994) . To maximize the accu racy of assessments, counselors can establish a nonjudgmental context; explicitly assure patients of privacy and confidentiality; explain why questions are being asked (when the purpose of questions is not obvious to a patient); consider the impact of related problems (such as psychiatric or legal difficulties) on assessment of risk behaviors; and, where appropriate and feasi ble, use self-administered or computerized tests to eliminate the need for patients to report socially sensitive information face to face.
Laboratory Testing and Counseling
Given the demonstrated clinical value of medical and psychosocial interventions to treat and prevent HIV, drug abuse treatment programs should offer HIV test ing and counseling. The only exceptions would be programs that see patients for shorter periods than the time needed to obtain test results and provide feed back. In general, IDUs who know they are infected engage in high-risk activities less frequently than those who are not infected or do not know their HIV sta tus. While patients newly diagnosed with HIV occa sionally develop stress reactions and inject drugs more frequently, such responses are generally transient and not usually associated with the increases in risky injec tion behaviors that can lead to further HIV trans mission. Supportive pretest and post-test counseling, which can anticipate such reactions and reduce their impact, are an indispensable part of the testing process.
The rates of false positive reactions among HIV tests (which routinely include both ELISA and Western Blot assays) are extremely low; hence, any confirmed positive test should be taken as evidence of HIV infec tion. In the rare circumstances in which HIV Western Blot results are indeterminate, individuals should be referred for expert evaluation.
Blood tests can indicate whether a patient is sus ceptible to hepatitis A or B (and thus should receive vaccine) or has antibodies that reflect previous expo sure and immunity (in which case vaccination is not needed). The tests can also reveal whether a patient has active or resolved hepatitis B infection. For the hepa titis C virus, an antibody test reveals only prior expo sure to the virus and does not indicate whether the infection is new (acute), chronic (long-term), or resolved. Findings indicating chronic active hepatitis B infec tion or evidence of exposure to hepatitis C infection should prompt referral for clinical evaluation and pos sible treatment. Screening for hepatitis B has been rec ommended as a routine part of care in drug abuse treat ment programs (Center for Substance Abuse Treatment, 1995; www.health.org/govpubs/bkd131/) , and these pro grams are valuable settings for hepatitis A and C screen ing, as well. For more specific guidance in the inter pretation of hepatitis tests, see box,"How To Interpret Hepatitis Test Results," page 7.
PRIMARY PREVENTION OF INFECTION
We use "primary prevention" to describe strategies to limit the drug abuse patient's exposure to infectious agents and to minimize the impact of such expo sure. Primary prevention efforts include education and counseling, vaccination, and outreach to bring IDUs into treatment.
Risk Education
To address the problem of HIV/AIDS among patients and their contacts, drug abuse treatment programs have incorporated education about reducing risky behavior as part of drug counseling protocols. Gibson and colleagues (1998; also http://hivinsite.ucsf.edu/ InSite.jsp?page-kb-07&doc=kb-07-04-01-01) reviewed the controlled research evaluations of a range of coun seling interventions aimed at preventing IDUs from acquiring HIV/AIDS. They found that more inten sive interventions-that is, those with more patient contact-seemed to reduce risky injection drug use practices and sexual behaviors more than did less inten sive interventions. Components of successful programs include individual or group counseling sessions focused on skill-building, relapse prevention, and HIV coun seling and testing.
Drug abuse treatment programs and syringe exchange programs (SEPs) can improve, however, at providing hepatitis prevention education and inter ventions. In a recent survey at two New York City SEPs, the majority of IDUs had previously been in drug abuse treatment. Although most were concerned about hepatitis, most had not been tested for hepati tis C virus, were not aware that vaccines were avail able to prevent hepatitis A and B, and did not know that hepatitis C therapy existed (Perlman et al., 2001) .
While there is debate about the optimal approach to hepatitis C treatment for active drug users (Edlin et al., 2001) , few would argue against providing edu cation about how to reduce risks for hepatitis as part of drug abuse counseling. Those entering drug abuse treatment should be provided with education about viral hepatitis and offered hepatitis testing. Counseling can help prevent new infection among those who are still susceptible and help those already infected to avoid transmitting the disease to others. The content of coun seling should reflect emerging evidence that sharing of cottons and cookers transmits hepatitis C, that riskreduction strategies applied to HIV prevention can also help to prevent hepatitis transmission, and that vaccination for hepatitis A and B may be important if the patient is susceptible.
Patients with chronic hepatitis B infection or recent or chronic hepatitis C infection should be advised that treatment exists that can help prevent progres sion of the disease, and they should be referred for evaluation for therapy. Chronic hepatitis B infec tion or other liver disease may be treated with lamivu dine, which is associated with improvement in liver function in more than 50 percent of patients treated. Treatment of chronic hepatitis C infection with alpha interferon agents alone (either alpha interferon or PEG-alpha interferon) or in combination with rib avirin may prevent progression of, or even reverse, liver disease in infected patients. Overall, about 30 to 40 percent of all patients can expect to have sustained 
How To Interpret Hepatitis Test Results

Hepatitis B
• The absence of any hepatitis B markers demonstrates susceptibility to hepatitis B; vaccination is indicated.
• The presence of hepatitis B surface antigen demonstrates active hepati tis B infection, which may progress to chronic liver disease. False posi tive tests are extremely uncommon.
• The presence of hepatitis B surface antibody demonstrates immunity to hepatitis B, either from prior vaccination (in which case the hepatitis B core antibody would be negative) or from prior naturally acquired but resolved disease (in which case hepatitis B core antibody would be positive).
• Some individuals may have isolated hepatitis B core IgG antibody reac tivity. This may be due to either low-level active infection (in which case a hepatitis B DNA test would be positive) or very remote resolved hepa titis B infection with loss of hepatitis B surface antibody over many years (the development of hepatitis B surface antibody in response to a dose of vaccine confirms this)or to a false positive hepatitis core anti body test. In the latter instance, hepatitis B vaccination is indicated.
Hepatitis C
• Hepatitis C antibody reactivity means that hepatitis C infection is likely. Referral for clinical evaluation is indicated to confirm active hepatitis C infection by documenting detectable hepatitis C virus by a viral load assay, to assess for liver disease with liver function tests, and possibly, to conduct a liver biopsy to consider treatment of hepatitis C. 
What a Drug Treatment Program Can Do To Incorporate HIV/Hepatitis Prevention Assessment and Diagnosis
Limiting the Consequences of Disease (Secondary Prevention)
Link patients to or provide primary medical care (active referral strategies, on-site care) Link patients with agencies that address their problems with retention in medical care and drug abuse treatment Promote medication adherence: reminder systems, social support, incen tive strategies
General Information and Communications
Keep abreast of changing research, ethical and legal issues Educate staff and community about medical complications of drug abuse and treatment options Join community leaders and patient representatives in providing informa tion about how to address HIV and hepatitis more effectively viral clearance with the combination of an interferon agent and ribavirin. Recent data suggest that the treatment of acute hepatitis C can prevent the establishment of chronic hepatitis C infection (Jaeckel et al., 2001) . 
Vaccines
Although there is not yet any vaccine against hepati tis C, vaccination can prevent hepatitis A and B. For those with chronic hepatitis C infection who are susceptible to hepatitis A or B, vaccination is impor tant, since infection with other forms of hepatitis may lead to liver failure. The rates of vaccination for hep atitis A and B are low among IDUs, however, sug gesting lost opportunities for prevention. The most successful vaccine delivery systems to date are those that either administer vaccines at the drug abuse treat ment site or use incentives to encourage patients to follow through on being vaccinated elsewhere. Models based solely on providing vouchers for free vaccines have produced less impressive rates of completed immu nization (Des Jarlais et al., 2001) . Two vaccines for hepatitis A and two for hepa titis B have been approved for use in the United States. They should not be given to patients with prior hyper sensitivity to the vaccines or their components. Hepatitis A and hepatitis B vaccines may be used together, gen erally minimizing inconvenience to patients without increasing adverse effects or decreasing effective ness. Providing the two vaccines at the same time may also increase the likelihood that patients will complete the vaccine series. The hepatitis A vaccine is given at month 0 (the start of hepatitis treatment) and 6 months; the hepatitis B vaccine is given at 0, 1, and 4 to 6 months. Alternatively, for patients who need immunization against both hepatitis A and B, a recently approved combination vaccine may be used (at 0, 1, and 4 to 6 months) to reduce the number of injec tions.
Although complete courses of each vaccine are needed for optimal benefit, there is significant clini cal value to patients who receive incomplete courses or even single doses; therefore, there is no need to guar antee that a patient will complete the series before ini tiating vaccination. To ensure that susceptible drug abusers receive at least one vaccine dose, the usual practice is to obtain a blood sample for testing and administer a first dose of vaccine at the initial visit.
Hepatitis B vaccination in SEPs has been a useful component of the public health response to a hepatitis B outbreak among IDUs in Pierce County, Washington. A pilot study of SEP-based hepatitis B vaccination in New York City had an 83-percent rate of completed vaccine series (Des Jarlais et al., 2001 ).
Outreach to IDUs
Drug abuse treatment programs can build ties to other community-based programs for cooperative efforts in HIV and hepatitis prevention. Some SEPs offer HIV counseling and testing, flu and pneumonia vaccines, and other medical services either at the program site or by referral elsewhere. Many SEPs provide preven tion services in neighborhoods where drug users live to reach those who are unwilling or unable to use con ventional services elsewhere. SEPs can also promote prevention by linking IDUs-including those con tacted through outreach efforts such as field workers' visits to homes and shooting galleries-with drug abuse treatment. In one study, Heimer (1998) found that both SEP and non-SEP clients used the SEP to obtain referrals to drug abuse treatment, and of those requesting treatment, 60 percent started therapy. Moreover, compared with clients referred by other sources, drug users referred by SEPs have comparably good short-term drug abuse treatment outcomes.
HIV counseling and testing centers where drug users present for confidential or anonymous HIV test ing have the potential to serve as sources of referral to drug abuse treatment, medical care, and other pre vention services. The advantage of this approach is that the initial contact may afford the provider an opportunity to engage the patient in ongoing pre vention and drug abuse treatment services.
Community outreach, which relies on peers and community residents to identify out-of-treatment drug users and initiate risk-reduction counseling, may also serve as a conduit to prevention services. Basic riskreduction activities usually include raising aware ness about HIV and other blood-borne diseases, teach ing skills to reduce risky drug use and sexual behaviors, providing materials for protection (for example, con doms and bleach), and counseling and testing for HIV. Studies show that outreach interventions are effective in reducing risky injection drug use practices and increasing protective behaviors, including entry into drug abuse treatment, needle disinfection, and con dom use (Coyle et al., 1998) . Drug treatment per sonnel could benefit from reading NIDA's manual on how to conduct effective community outreach (NIDA, 2000) .
In summary, linkages between drug abuse treat ment programs and community-based prevention serv ices, such as SEPs and HIV counseling and testing centers, have the potential to reduce the risk of both HIV and hepatitis. Creating formal agreements or linkages between drug abuse treatment programs and these referral sources may assist drug users in access ing drug abuse treatment, prevention, and health care services.
SECONDARY PREVENTION: LIMITING DISEASE CONSEQUENCES
The term "secondary prevention" here refers to inter ventions for people who are already infected with HIV or hepatitis. The goals of secondary prevention are to limit the medical consequences of infection and dimin ish the further spread of the disease. An excellent man ual for drug abuse treatment providers offers a range of tips and suggestions (Center for Substance Abuse Treatment, 2000) , including ways to incorporate pri mary medical care, mental health, and social serv ices into drug abuse treatment programs; to link with other "wrap-around" services such as case manage ment; and to keep abreast of changing legal and eth ical issues of treating people who have HIV infection.
Links to Primary Care
Patients in drug abuse treatment may encounter sub stantial barriers to receiving health care, such as lack of insurance or transportation, perceived attitudes of providers, social disorganization, and competing pri orities. Patients generally receive few medical services while in drug abuse treatment, yet drug treatment pro grams can play a critical role in determining outcomes such as acceptance of therapy, appointment-keeping, and adherence to medication schedules.
Research has provided a growing body of evi dence that delivering medical and psychosocial serv ices at drug abuse treatment sites increases patients' utilization of primary medical care, medical screen ing, and mental health services; improves medication compliance and medical outcomes, retention in treat ment, and substance use outcomes; and reduces emer gency room visits (e.g., Selwyn et al., 1989) . Moreover, HIV-related medical care programs incorporated into drug abuse treatment settings show high rates of uti lization and medication compliance and have the potential to deliver hepatitis prevention services to drug users (Selwyn et al., 1989) .
Service delivery models that provide medical care onsite at drug abuse treatment programs (or nearby) have several advantages, including attention to mul tiple service needs during a single visit, enhanced com munication between drug treatment and primary care providers, and the ability to accommodate patients who at times visit without appointments. Combining drug abuse treatment with regular medical care is asso ciated with fewer subsequent hospitalizations. Therefore, averting costs of inpatient stays by promoting conti nuity of medical and drug abuse treatment either onsite or through linkage mechanisms may prove to be a costeffective model of care for drug abusers.
Links to Other Services
Relatively few studies have examined the effectiveness of various linkage mechanisms to promote use of med ical services among individuals enrolled in drug abuse treatment programs. Linkage strategies that have been used to improve drug abuse patients' access to med ical care include case management and transportation. Findings on the utility of case management to increase access to medical care have been mixed, however, and successful case management may not be possible with out funding initiatives to support such programs. Although few studies have examined the influence of transportation on utilization of drug abuse treatment services, some evidence suggests that transportation may be an important linkage mechanism (Friedmann et al., 2000) .
Promoting Medication Adherence
By helping patients take needed medications, drug abuse treatment programs can play an important role in the delivery of HIV/hepatitis preventive and med ical services. Any hepatitis vaccination program must consider issues of adherence, as completion of the vac cine series affords optimal protection. Specific data on factors affecting retention of IDUs in hepatitis pre vention programs are sparse, but a number of drug use, demographic, and behavioral factors have been associated with patients' failure to comply with treat ment for drug abuse, TB, and HIV and with other medical interventions. Hence, programs designed to deliver HIV and hepatitis prevention interventions to IDUs in treatment settings should make use of strategies demonstrated or likely to promote greater adherence, such as positive reinforcement, incentives, and other strategies (see box, "What a Drug Treatment Program Can Do To Incorporate HIV/Hepatitis Prevention," page 8).
CONCLUSION
Staffs in drug abuse treatment programs have con siderable ability to prevent, detect, and diminish the adverse consequences of HIV and hepatitis A, B, and C viruses. The boxed text summarizes the evidencebased interventions that we recommend. Many of these activities (for instance, educating the staff about hep atitis) do not require additional resources, and some, such as building linkages to potential affiliate pro grams, make good sense for any organization. Other potentially valuable interventions may not be feasible within a treatment program's current budget; for exam ple, vaccinating patients for hepatitis A and B may be beyond the services usually provided. Many of these interventions require the involvement of the com munity's public health leadership. Combining drug abuse treatment with both hepatitis vaccination and interventions to reduce risk behaviors has the poten tial to be a highly efficient, synergistic approach to hepatitis prevention for IDUs and their contacts.
Drug treatment programs are in a pivotal posi tion to reach a population that is at risk for HIV and hepatitis and has high prevalence of those diseases. Researchers and practitioners can be a powerful team, especially working with policymakers, to determine how drug abuse treatment programs can prevent HIV and hepatitis in their communities, to further dis seminate research-based interventions, and to bring many of the new HIV and hepatitis strategies into local treatment settings.
